Fadila Kouhen*, Hanae El Gouach, Meriem Damou and Mohammed Sqalli Houssaini
The idea clinical trial presented at the esteemed San Antonio breast cancer symposium and simultaneously published in the journal of clinical oncology sheds light on a specific subset of breast cancer management. This singlearm study included 200 postmenopausal patients (aged 50-69) with pT1N0 invasive breast cancer, ER-positive, PRpositive, HER2-negative and an Oncotype DX score ≤ 18. Following Breast Conserving Surgery (BCS) with margins ≥ 2 mm, patients were enrolled to explore radiotherapy omission, given they consented to at least 5 years of endocrine therapy. The primary endpoint was the 5-year locoregional recurrence rate post-BCS. Conclusively, the IDEA trial indicates effective high disease control at 5 years without radiotherapy.
Published Date: 2025-02-28; Received Date: 2024-03-28
